The WHO anatomical therapeutic chemical (ATC)/defined daily dose (DDD) methodology is a standardized method of comparing antimicrobial use. The ATC/DDD is defined as the average maintenance daily dose of a drug used in a 70 kg adult, ignoring the considerable differences in body weight of neonates and children. The aim of this study was to develop a new standardized way of comparing rates of antimicrobial prescribing between European children's hospitals.
Introduction
Many studies have shown that pre-school children are very high receivers of antibiotics and that the use of antibiotics in children varies markedly between European countries. 1 -4 In view of the rising rates of antimicrobial resistance in Europe and the extremely limited new antibiotic pipeline, it is important to reduce inappropriate neonatal and paediatric antibiotic use. Many hospitals in Europe and the USA are developing Antimicrobial Stewardship Programmes (ASPs), which are based on regular audit and feedback of hospital-specific trends in local antimicrobial prescribing rates. There has been very limited development of ASPs in paediatrics, due in part to the lack of a standardized method of comparing antimicrobial use between units.
The defined daily dose (DDD) is defined as the average standard daily dose of a drug used in a 70 kg adult and has been used extensively to compare rates of antimicrobial use between hospitals and countries. A small number of studies have used the DDD methodology in children, 5 -8 including two recent comparisons of antimicrobial use in paediatric and neonatal units 9 -11 and more recently a study applying prescribed daily dose (PDD) methodology. 12 The disadvantage of using the adult anatomical therapeutic chemical (ATC)/DDD methodology 13 to compare paediatric antibiotic prescribing is that it does not take into account either the weight or the age of the child. By definition, the total DDD from an adolescent ward would be much higher than that from a neonatal unit, making direct comparisons very difficult between hospitals with a different case mix. We therefore collected antibiotic use and dosing pilot data in children and neonates from four European hospitals with the aim of developing a new neonatal and paediatric DDD methodology.
Methods

Data collection
Data were collected from four hospitals in three European countries (the UK, Italy and Greece) between February 2009 and May 2009 (study period). Data were collected from the following hospitals: in the UK, St George's Hospital (Centre 1) from 9 to 22 February and Evelina Children's Hospital (Centre 2) from 11 to 24 March; in Italy, Department of Maternal and Paediatric Sciences, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (Centre 3) from 16 to 29 April; and in Greece, P. and A. Kyriakou Children's Hospital (Centre 4) from 13 to 26 May. A 14 day point prevalence survey (PPS) period was chosen over the usual 1 day to obtain maximum data to develop the comparator methodology. A single investigator (A. P.) collected the data during 14 consecutive days in the paediatric and neonatal wards in the four centres over a 3 month period. Prescriptions were assessed daily and data were collected for each patient on age, sex, weight, underlying diagnosis and antibiotics used, including dose, frequency and route of administration.
Hospital description
All hospitals were tertiary paediatric centres catering for patients with complex medical and surgical problems, including delivery of paediatric intensive care. All neonatal units cared for extremely premature babies. The neonatal unit at Centre 4 was temporarily closed to admissions and was therefore excluded from the overall analysis. New neonatal and paediatric PPS forms were developed based on the European Surveillance of Antimicrobial Consumption (ESAC) PPS (www.esac.ua.ac.be) and the new European Centre for Disease Prevention and Control (ECDC) Healthcare-Associated Infections (HAI) and Antibiotic PPS forms (http ://ecdc.europa.eu/en/activities/surveillance/hai). Paediatric-specific rules to define the underlying medical or surgical condition, the clinical indication for treatment, drug dosage and demographics, including ward occupancy, were also derived from the ESAC rules for conducting a PPS. Antibiotic drugs were coded based on the WHO ATC classification and the DDD was defined using the WHO recommendations. 13 
Data analysis
Descriptive analyses for demographic data, antibiotic use, underlying chronic condition and current diagnosis have been reported previously. 14 For this study, we initially described the simple proportion of children and neonates on antibiotics during the survey and the DU90%, defined as the number of antibiotics that accounted for 90% of the total amount of DDD prescribed, in each unit. The next step was to present the dosing of the most frequently used antibiotics overall and by specific weight bands. Finally, we compared two methods to demonstrate the variation in antibiotic use in children and neonates between the centres: (i) the standard adult ATC/DDD method; and (ii) a PDD-based method. The DDD was expressed as the number of DDD/100 bed days. The ATC/DDD calculation (as used in a previous study 8 ) was DDD/100 bed days¼[consumption of antibiotic (g)×100]/[DDD (g/day)×total admissions]. The number of occupied bed days, defined as the sum of single overnight hospital stays by a neonate or child during the study period, served as the denominator for the PDD and DDD calculation. The PDD (g) was calculated as: body weight (kg)×prescribed dose (mg/kg/day)/100. Analysis was then performed grouping the data into specific weight bands to allow comparison between centres caring for children of different ages. In view of the small overall numbers we defined three paediatric weight bands (,10 kg, 10-,25 kg and ≥25 kg) and prescriptions from the neonatal unit/ward were analysed separately, as there are frequently very different antimicrobial resistance and use patterns between neonatal intensive care units and paediatric wards. Analyses were carried out using Stata version 11.0 (Statistical Software: Release 11, College Station, TX, USA).
Ethical approval
This study was a completely anonymized audit of current antibiotic prescribing practice. No unique identifiers were collected. Local guidelines from each participating country confirmed that formal ethical approval was not required.
Results
Variation in the proportion of neonates and children receiving antibiotics between hospitals During a 14 day period a total of 1217 antibiotic prescriptions from four hospitals were issued for 605 hospitalized patients (145 at Centre 1, 182 at Centre 2, 132 at Centre 3 and 146 at Centre 4). A total of 954 prescriptions were issued for 505 paediatric and 263 for 100 neonatal admissions ( Table 1 ). The cohort has been described previously. 14 
Variation in the type of antibiotic prescribed
Antibiotic use varied considerably by ATC group and centre. Overall, 47 different antibiotics were used, with numbers prescribed ranging between 20 and 30 in the paediatric units (P,0.05) and between 9 and 11 in the neonatal units (P ¼ 0.602). DU90% was significantly different in the paediatric units [highest at Centre 1 (15), 12 at Centres 2 and 4, and lowest at Centre 3 (8)]; in neonatal units there was no significant difference (Table 1 and Figures S1 and S2, available as Supplementary data at JAC Online).
The penicillin b-lactam antibacterials (J01C) were the most frequently used antibiotics overall (37% of all antibiotics used) ( Table 2 ). The type of b-lactam used also varied between centres, e.g. co-amoxiclav (J01CR02) was more commonly prescribed in Centres 1 and 2 in the UK compared with Centres 3 and 4. At Centres 3 and 4, cephalosporins (other b-lactam antibacterials, J01DB-J01DE, J01DI) were more commonly used (ceftriaxone/cefotaxime at Centre 3 and cefuroxime/ceftriaxone at Centre 4). The penicillin b-lactams (J01C) were also the most common prescriptions in all three neonatal units, accounting for 40%, 41% and 34% of total use at Centres 1, 2 and 3, respectively.
The overall most common indication for antibiotic use across the paediatric units was surgical prophylaxis (21%). The proportion of surgical prophylaxis varied from 2% at Centre 1 to 18% at Centre 3 and 31% at Centres 2 and 4. The main indication for antibiotic treatment was lower respiratory tract infection in 49 (17%) children at Centre 2 and 59 (37%) at Centre 3. In contrast, the main indication for antibiotic treatment at Centres 1 and 4 was surgical management [69 (26%) and 59 (36%), Porta et al.
Variation in antibiotic dosing between centres using a weight-based method (mg/kg/day)
As it is not feasible to compare dosing for all the 47 different antibiotics used in this PPS, a detailed analysis was only performed for the most commonly prescribed antibiotics on the paediatric wards. We have used ceftriaxone and co-amoxiclav as examples to compare the dosing and overall drug use between units. Paediatricians are used to dosing based on mg/kg/day. The overall prescribing of ceftriaxone varied significantly among the four hospitals, with higher doses (based on mg/kg/day) prescribed at Centre 4 and Centre 3 compared with the UK centres (P ¼ 0.004) (Figure 1a) . The median dosing for The median prescribed doses of oral co-amoxiclav also varied widely: it was 32 and 39 mg/kg/day at Centre 1 and Centre 2, respectively, compared with 54 mg/kg/day at Centre 4 and 70 mg/kg/day at Centre 3 (P ¼ 0.005) (Figure 2a) . Overall, the dosing range was 23 -102.3 mg/kg/day. When co-amoxiclav dosing was broken down by age, it appears that the largest variation in dosing occurred in patients under 1 year old (P,0.05) (Figure 2b ). Porta et al.
Comparing total antibiotic consumption between hospitals using either a DDD or a PDD method
Total antibiotic use presented in DDD and PDD/100 bed days
Measuring the consumption of all antibiotics in each centre with the DDD method identified the highest antibiotic prescribers as Centre 3 and Centre 1 ( Table 1) . Centre 1 was also the highest antibiotic user when a PDD method was used, with 50 PDD/100 bed days; Centre 4 had the second highest PDD (39.6/100 bed days). Interestingly, comparison of the total use of antibiotics in the three neonatal units showed that overall DDD consumption was similar across the units, with 1.06 DDD/100 bed days at Centre 1, 1.09 DDD/ 100 bed days at Centre 2 and 0.97 DDD/100 bed days at Centre 3.
Comparing individual antibiotics by different methodsconsumption of ceftriaxone for all ages and by weight bands using DDD or PDD/100 bed days First, the DDD and PDD methods were used to compare overall ceftriaxone consumption (Table S1 , available as Supplementary data at JAC Online). Ceftriaxone use combined across all four centres was 1.0 DDD/100 bed days and 2.0 PDD/100 bed days, with Centre 1 using 1.72 DDD/100 bed days compared with the lowest-using centre, Centre 4, using 0.3 DDD/100 bed days. The influence of weight on DDD is clearly seen in the ceftriaxone DDD consumption of 0.42/100 bed days and PDD of 0.98/100 bed days in 13 children ≥25 kg. This compares with 23 infants ,10 kg with 0.17 DDD/100 bed days and 0.33 PDD/100 bed days.
Consumption of all J01D (other b-lactam antibiotics) overall and by weight bands applying DDD or PDD/100 bed days
We analysed the use of J01D (other b-lactam) antibiotics overall, then by centre and weight band. See Table 3 . This ATC group includes first-to fourth-generation cephalosporins, monobactams and carbapenems and is responsible for almost a third of all prescriptions. J01DI, active against methicillin-resistant Staphylococcus aureus (ceftobiprole medocaril and ceftaroline fosamil), which are also coded J01D, were not used at any centre. Centre 4 was the highest user of J01D antibiotics, with 6.08 DDD/ 100 bed days and 17.57 PDD/100 bed days. The large difference in these results using the two different methods is explained by the high absolute doses prescribed for the cephalosporins causing the PDD to increase. For example, J01D was prescribed 64 times at Centre 2 versus 66 times at Centre 3, but Centre 2 had only approximately half of the DDD/100 bed days compared with Centre 3 (2.14 and 4.13 DDD/100 bed days, respectively). This reflects both the overall lower doses used in the UK and the fact that almost half of the children receiving ceftriaxone at Centre 2 were in the lowest weight band, while at Centre 3 many more children receiving ceftriaxone were in the 10 -,25 kg weight band (Table S1 ). The use of J01D antibiotics at Centre 1 also clearly illustrates that children with higher weights are inevitably prescribed larger overall doses of antibiotics; 14 children with a weight ≥25 kg used 2 DDD/100 bed days compared with 0.59 DDD/100 bed days in 15 children with a weight ,10 kg. We therefore propose a simple algorithm to compare antimicrobial exposure between hospitals (Figure 3) . Developing a new paediatric methodology to compare antibiotic prescribing
Discussion
A variety of methods have been developed to compare differences in antimicrobial use and the quality of prescribing between hospitals. In part these reflect the availability of different data sources, as centres tend to report what they can measure. Within Europe there are few standardized hospital electronic prescribing databases providing information on antimicrobial use. This has led to the successful development of PPSs as a standardized web-based tool. 12, 15 The advantage of a PPS is in determining the proportion of children on antibiotics, but also providing information on the type of antibiotic used, indication and dosing. Another method often used is days of therapy (DOT), which has the advantage of apparent simplicity, is reproducible and allows direct comparison between hospitals (when adjusted for case mix), but is ideally performed in settings with large databases including international statistical classification of diseases and health-related problems [International Classification of Diseases (ICD)] 9/10 coding, duration of stay and antimicrobial use. 16 The simplest method is just the proportion of children on antibiotics, combined with the use of DU90% profiles. These can also be used as a marker of the quality of antimicrobial prescribing if they can be linked to hospital-specific guidelines. In the absence of large electronic prescribing databases, we believe the use of PPS data may add value to the simple descriptive indicators to prospectively monitor antimicrobial use in children, if a standardized method can be agreed on.
Main findings
This study has identified that across four hospitals in Europe almost half of all paediatric admissions received antibiotic treatment. A surprisingly large number of different antibiotics were prescribed, which was only partly explained by the different underlying chronic conditions and indications. There was a wide variation in the type of antibiotic used, co-amoxiclav being most common at Centres 1 and 2-both UK hospitals-whereas cefotaxime and cefuroxime were most common at Centre 3 and Centre 4, respectively. In neonatal units, aminoglycosides in combination with benzylpenicillin or flucloxacillin were the most common prescriptions at Centres 1 and 2, while vancomycin combined with amikacin or gentamicin was used more frequently at Centre 3. There is also very marked variation in drug doses used across Europe, even for commonly used antibiotics.
Comparison with previous findings
There have been few studies directly comparing antibiotic use between different children's hospitals. The largest studies recently published have been from China, comparing five large children's hospitals over a 5 year period. 8 Changes over time were measured using DDD/100 bed days and a fall from 72.1 DDD/ 100 bed days in 2002 to 35.5 in 2006 in paediatric intensive care was noted, which is comparable to the levels of consumption seen in this study. While this method has potential utility for measuring changes in antibiotic use within a unit over time as long as the case mix remains stable, it does not allow formal comparison of drug use between hospitals.
Potential study bias
There are a number of potential biases in any survey across Europe, including observer bias and data entry errors. A single researcher conducted the PPS across all hospitals for every day of the 2 week period and undertook all data collection and entry in order to minimize these errors and to reduce the variation in interpretation of underlying and current clinical diagnoses. The
Step 1
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Step 3
Description of DU75% or DU90% (with an increasing number of centres preferring DU90%) and the proportion of children on antibiotics by weight/age bands Description of doses in mg/kg/day used for the most frequently prescribed antibiotics by weight/age bands Description of antibiotic use in DDD/100 bed days by weight/age bands Porta et al.
hospitals were not selected to provide representative data on antimicrobial use across Europe, but to obtain data to derive a standardized comparator method. A bias was introduced due to seasonality because of the wide time span of the survey; however, the study was planned to collect data only to devise new antimicrobial comparators.
Paediatric DDD methodology
We have described and compared the overall numbers of antibiotics used between hospitals and the DU90%, which enables a simple comparison between centres. Subsequently we compared dosing of the most commonly prescribed antibiotics in each unit, using mg/kg/day. It emerged that the significant difference in dosing seen between hospitals was mainly due to the dosing differences in the younger age groups. Whether this reflects different dosing recommendations for varying clinical indications or differences in the Summary of Product Characteristics for different age groups in specific countries is unclear, but it clearly highlights the need to present data by age/weight bands. Interestingly, it was noted that the UK dosed consistently lower for all antibiotics for the same indication and age than the other European centres. The variation between DDD/100 bed days (also known as DBD) and PDD/100 bed days methodology is highlighted by the difference between 4.27 DDD and 12.1 PDD/100 bed days of J01D seen overall. Broadly, the PDD method provides more of an insight into the amount of specific drugs consumed compared with the DDD method, but the use of DDD/100 bed days allows summation of antibiotic use across drug groups. In contrast to adult studies, in paediatrics any DDD-derived method gives very limited information regarding the real number of children actually receiving antibiotics, and this study demonstrates that similar overall DDD results may hide large dosing variations. For example, a unit with frequent underdosing but admitting older children may appear to have an average consumption. Therefore, using some form of age or weight bands (the latter being more logical for describing antibiotic use) should give a better understanding of the pattern of antimicrobial use in the different units. We propose the separate analysis of neonatal units, and then having three simple paediatric bands, based on weights that both approximate to specific surface areas and ages and also reflect in part the pharmacokinetic maturation phases during neonatal and paediatric life. When presenting the data in these four groups, the numbers for individual antibiotics became too small to allow meaningful comparison, so combining antibiotics using ATC groupings was explored.
We therefore suggest a new three-step algorithm as a combination of the methods described above, which might provide a useful and scientifically valid method of comparing both antibiotic consumption and the quality of prescribing between different children's hospitals. The first step requires just a simple comparison of the DU90% and the proportion of children on antibiotics in each unit. The second step describes dosing variation overall and within the four specific weight/age groups. The third step describes the total and ATCgrouped antibiotic use in DDD/100 bed days, also presented by weight/age groups.
Conclusions
We investigated different methods to assess DDD use in paediatric and neonatal units across four European hospitals in this study and have produced a new method for comparing antibiotic exposure across neonatal and paediatric units. In Europe, the Antibiotic Resistance and Prescribing in European Children (www.arpecproject.eu) is a DG SANCO funded project now conducting a web-based neonatal and paediatric antimicrobial PPS across 20 different European children's hospitals. The project will attempt to prospectively validate this method across these units. As this method requires only a simple 1 day PPS and webbased data entry, it has the potential to be a useful tool internationally to provide antibiotic use comparator data combined with educational feedback on antimicrobial stewardship.
